Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Assets Average (2022 - 2025)

Axsome Therapeutics' Assets Average history spans 4 years, with the latest figure at $679.5 million for Q4 2025.

  • For Q4 2025, Assets Average rose 20.28% year-over-year to $679.5 million; the TTM value through Dec 2025 reached $679.5 million, up 20.28%, while the annual FY2025 figure was $629.2 million, 8.78% up from the prior year.
  • Assets Average for Q4 2025 was $679.5 million at Axsome Therapeutics, up from $654.5 million in the prior quarter.
  • Across five years, Assets Average topped out at $679.5 million in Q4 2025 and bottomed at $134.6 million in Q2 2022.
  • The 4-year median for Assets Average is $565.0 million (2024), against an average of $504.0 million.
  • The largest annual shift saw Assets Average soared 271.89% in 2023 before it fell 8.48% in 2024.
  • A 4-year view of Assets Average shows it stood at $335.2 million in 2022, then soared by 77.36% to $594.5 million in 2023, then fell by 4.97% to $565.0 million in 2024, then rose by 20.28% to $679.5 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Assets Average are $679.5 million (Q4 2025), $654.5 million (Q3 2025), and $618.2 million (Q2 2025).